Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis

Stuart K. Sutton

doi:10.7326/L16-0627

Letters |7 February 2017

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis

Stuart K. Sutton, MD

Article, Author, and Disclosure Information

TO THE EDITOR:

I read Cusi and colleagues' (1) article about the benefits of pioglitazone in the management of nonalcoholic steatohepatitis in early or overt type 2 diabetes mellitus (T2DM) with interest yet also a sense of discouragement. As clinicians, we are frequently faced with patients who are understandably concerned about this liver condition, yet we have little to offer beyond advice on lifestyle measures. Although their research showed impressive benefit with the use of pioglitazone, the legal climate surrounding this drug, if not the entire class to which it belongs, is virtually certain to limit if not prevent its use in these patients.

FULL TEXT

PDF

Not Available

2017 American College of Physicians

Letters |7 February 2017

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis

See Also

Content

Information For

Services

Awards and Cover

Other Resources

Follow Annals On

Letters |7 February 2017

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis

See Also

Content

Information For

Services

Awards and Cover

Other Resources

Follow Annals On

You need a subscription to this content to use this feature.